首页 > 市场调查报告书 > 製药

眼科药物

全球视网膜疾病药物市场 (2022-2028)：按类型、剂型和分销渠道分列的规模、份额、增长分析和预测

市场调查报告书

商品编码

1270798

全球视网膜疾病药物市场 (2022-2028)：按类型、剂型和分销渠道分列的规模、份额、增长分析和预测

Global Retinal Disease Therapeutics Market Size, Share, Growth Analysis, By Type, By Dosage forms, By Distribution Channel - Industry Forecast 2022-2028

出版日期: 2023年04月11日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

视网膜疾病药物市场规模2021年将达到114.9亿美元，2022年将达到125.7亿美元，2023年至2030年预测期内復合年增长率为9.3%，预计2030年将增长至256.9亿美元.

全球有超过 2.53 亿人患有视网膜疾病，预计这将在未来几年对医疗保健行业造成重大经济负担。此外，由于81%的视障患者年龄在50岁以上，预期寿命的增加也将给眼科医疗行业带来沉重负担。由于糖尿病在新兴国家的流行，包括糖尿病性视网膜病变、糖尿病性黄斑水肿等在内的视网膜疾病病例不断增加。未来，全球范围内专门治疗视网膜疾病的专家数量将增加，有望推动市场的扩张。此外，到 2028 年底，许多国家收紧昂贵的视网膜疾病治疗报销政策也有望支持市场扩张。

在本报告中，我们调查了全球视网膜疾病药物市场，并提供了市场概况、市场各种影响因素分析、技术和创新趋势、市场规模的转变和预测，总结了细分，竞争格局、主要公司概况等。

内容

执行摘要

市场概览

母市场分析

市场概览

市场规模

市场动态
司机
机会
约束因素
任务
SWOT 分析

主要市场洞察

技术分析
价格分析
供应链分析
价值链分析
市场生态系统
知识产权分析
贸易分析
启动分析
原材料分析
创新矩阵
管道产品分析
宏观经济指标

COVID-19 的影响

经济影响：情景评估
修订市场规模
COVID-19 对主要细分市场的影响
企业 COVID-19 战略

市场动态和前景

市场动态
司机
机会
约束因素
任务
监管状况
SWOT 分析
波特的分析
Skyquest 对未来颠覆的特别洞察
全球视网膜疾病药物市场：按类型分类
黄斑变性
糖尿病视网膜病变
其他
全球视网膜疾病药物市场：按配方分类
凝胶
我的解决方案
胶囊剂和片剂
眼药水
药膏
全球视网膜疾病药物市场：按分销渠道分类
医院药房
在线药店
零售药房

按地区划分的市场规模

北美
美国
加拿大
欧洲
德国
西班牙
法国
英国
其他欧洲地区
亚太地区
中国
印度
日本
韩国
亚太其他地区
拉丁美洲
巴西
其他拉丁美洲地区
中东和非洲
海湾合作委员会国家
南非
其他中东和非洲地区

主要公司简介

竞争格局
目标公司数量
主要公司的定位
主要公司的市场份额
Merck and Co., Inc.
Novartis AG
Allergan plc
F. Hoffmann-La Roche AG
Regeneron Pharmaceuticals, Inc.
Santen Pharmaceutical Co., Ltd.
Shire（Takeda Pharmaceutical Company Limited）
Bayer AG
Graybug Vision, Inc.
Acucela Inc.（Kubota Pharmaceutical Holdings Co., Ltd.）.

简介目录

Product Code: SQMG35H2021

Global Retinal Disease Therapeutics Market size was valued at USD 11.49 billion in 2021 and is poised to grow from USD 12.57 billion in 2022 to USD 25.69 billion by 2030, growing at a CAGR of 9.3% in the forecast period (2023-2030).

Over 253 million individuals worldwide suffer from retinal abnormalities, which are a rising problem in both developed and developing countries and are predicted to put a considerable financial burden on the healthcare industry in the years to come. The rising life expectancy of the population is expected to put significant strain on the ophthalmic care industry, as 81 percent of patients with vision impairment are over 50. Because diabetes is more common in emerging nations, there are more cases of retinal diseases including diabetic retinopathy, diabetic macular edoema, etc. As more qualified professionals that specialise in the treatment of retinal illnesses become available globally over the course of the projected period, the market is anticipated to grow. Additionally, it is anticipated that by the end of 2028, enhanced reimbursement policies in numerous countries for the pricey treatment of retinal disorders will support market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of global Retinal Disease Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.

Segments covered in this report

Global retinal disease therapeutics market is segmented based on type, dosage form, distribution channel, and region. Based on type, the market is divided into macular degeneration, diabetic retinopathy and others. Based on dosage form, the global market is segmented into gels, eye solutions, capsules & tablets, eye drops, ointments. Based on distribution channel, the market is segmented into hospital pharmacy, online pharmacy, retail pharmacy. Based on region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and MEA.

Driver

An increase in the prevalence of eye disorders

The global market for retinal pharmaceuticals will be driven by the increased prevalence of eye-related disorders, particularly in industrialised nations. In 2016, 4.2 million Americans were among the 93 million people globally who have diabetic retinopathy, according to a report from the American Academy of Ophthalmology. By 2040, there will be 14.9 to 21.5 million early AMD cases and 3.9 to 4.8 million late AMD cases in Europe, predicts the NCBI. Growth in the worldwide retinal disease therapeutics market is anticipated to be driven by rising health education initiatives on eye disorders to encourage early treatment and prevent visual damage in emerging regions.

Growing Awareness Programmes for Retinal Diseases

To increase awareness of the diagnosis and available treatments for retinal diseases, several campaigns have been created internationally. The International Centre for Eye Health's goal is to increase public awareness of problems with eye health and accessible remedies. The World Glaucoma Association has been hosting the World Glaucoma Congress for the past six years to encourage discussion of new glaucoma treatments. To increase the use of age-related macular degeneration (AMD) treatments, the Macular Degeneration Association, Inc. holds seminars every month in a number of places. The rise of the retinal disease therapeutics market is anticipated to be fueled by these efforts' expected promotion of the use of various treatment modalities.

Restraint

The cost of treating retinal diseases is more expensive.

The high cost of retinal treatment techniques, patient complaints of short-term side effects, and long-term implications including infection and inflammation after laser eye surgery may all hinder the growth of the global market. Furthermore, dangers like accidental scleral perforation may occur during surgical procedures like pneumatic retinopexy, which could affect patient preferences and impede the expansion of the global market. The market for medicines for retinal diseases is also being hampered by the inadequate healthcare infrastructure in emerging nations.

Market Trends

High-End Technology Development to Support Market Development

Inherited retinal illnesses are frequently treated with retinal gene therapy. Gene therapy can treat vision impairment caused by the RPE65 gene mutation. Luxturna is a recently created gene therapy used to treat people with type 2 Leber's congenital amaurosis. It is a genetic disorder that affects vision from birth and causes a deterioration that progresses rapidly. Recombinant viruses are used in numerous retinal gene treatments that are now undergoing clinical trials. This aspect is anticipated to increase the market for therapies for retinal diseases globally between 2022 and 2028, the study period.

Executive Summary

Market overview

Exhibit: Executive Summary - Chart on Market Overview
Exhibit: Executive Summary - Data Table on Market Overview
Exhibit: Executive Summary - Chart on Global Global retinal disease therapeutics market Characteristics
Exhibit: Executive Summary - Chart on Market by Geography
Exhibit: Executive Summary - Chart on Market Segmentation
Exhibit: Executive Summary - Chart on Incremental Growth
Exhibit: Executive Summary - Data Table on Incremental Growth
Exhibit: Executive Summary - Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

Market Dynamics
Exhibit: Impact analysis of DROC, 2021
Drivers
Opportunities
Restraints
Challenges
SWOT Analysis

KEY MARKET INSIGHTS

Technology Analysis
(Exhibit: Data Table: Name of technology and details)
Pricing Analysis
(Exhibit: Data Table: Name of technology and pricing details)
Supply Chain Analysis
(Exhibit: Detailed Supply Chain Presentation)
Value Chain Analysis
(Exhibit: Detailed Value Chain Presentation)
Ecosystem Of the Market
Exhibit: Parent Market Ecosystem Market Analysis
Exhibit: Market Characteristics of Parent Market
IP Analysis
(Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
Trade Analysis
(Exhibit: Data Table: Import and Export data details)
Startup Analysis
(Exhibit: Data Table: Emerging startups details)
Raw Material Analysis
(Exhibit: Data Table: Mapping of key raw materials)
Innovation Matrix
(Exhibit: Positioning Matrix: Mapping of new and existing technologies)
Pipeline product Analysis
(Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
Macroeconomic Indicators

COVID IMPACT

Introduction
Impact On Economy-scenario Assessment
Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
Revised Market Size
Exhibit: Data Table on Global Global retinal disease therapeutics market size and forecast 2021-2027 ($ million)
Impact Of COVID On Key Segments
Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
COVID Strategies By Company
Exhibit: Analysis on key strategies adopted by companies